Switzerland has established itself as a global leader in the biotech industry, making significant advancements in areas such as cancer treatment, immunotherapy, gene and cell therapy, and more. With a strong focus on personalized and precision medicine, the Swiss biotech sector thrives on
The biopharmaceutical industry has seen significant advancements, particularly in the production of monoclonal antibodies (mAbs), which offer personalized therapies for a range of chronic and debilitating conditions. Despite these advancements, manufacturers face growing pressure to expedite the
The launch of the Planova FG1 by Asahi Kasei Medical marks a pivotal advancement in virus removal technology within the bioprocessing industry. This next-generation virus removal filter is designed to enhance efficiency and safety in the production of biotherapeutics, including biopharmaceuticals
Monoclonal antibodies (mAbs) have become a cornerstone of modern medicine, offering targeted therapies for a range of diseases, including various cancers, autoimmune disorders, and infectious diseases. However, developing these complex molecules is resource-intensive, requiring significant time and
The pharmaceutical industry is on the cusp of transformative changes over the next decade. Driven by new legislation and technological advancements, companies are rethinking traditional practices. The Biosecure Act, soon to be enacted in the US, and the rise of AI and automation, are key drivers of
The biopharmaceutical industry has witnessed significant advancements in upstream bioprocessing over the years, but downstream bioprocessing (DSP) often lagged, creating bottlenecks that hampered overall efficiency. Recent innovations, however, are transforming the DSP landscape, offering promising
